Portugal - portugali - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

mylan, lda. - tramadol + paracetamol - comprimido revestido por película - 37.5 mg + 325 mg - tramadol, cloridrato 37.5 mg ; paracetamol 325 mg - tramadol and paracetamol - genérico - duração do tratamento: longa duração

Euroopa Liit - portugali - EMA (European Medicines Agency)

ultragenyx germany gmbh - evinacumab - hipercolesterolemia - agentes modificadores de lipídios - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).

Euroopa Liit - portugali - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - anti-hemorrágicos - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Euroopa Liit - portugali - EMA (European Medicines Agency)

mylan ireland limited - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Euroopa Liit - portugali - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - agentes antineoplásicos - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Euroopa Liit - portugali - EMA (European Medicines Agency)

pfizer europe ma eeig  - axitinib - carcinoma, célula renal - inibidores de proteína quinase - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Euroopa Liit - portugali - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Brasiilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

grÜnenthal do brasil farmacÊutica ltda. - zolmitriptana - analgesicos contra enxaqueca

Brasiilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

grÜnenthal do brasil farmacÊutica ltda. - buprenorfina - analgesicos

Brasiilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

grÜnenthal do brasil farmacÊutica ltda. - naproxeno, esomeprazol magnésico tri-hidratado - agentes antiinflamatÓrios/antireumÁticos em associaÇÃo